SAN DIEGO, July 2, 2025 /PRNewswire/ — A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinicians monitor treatment response.
Study Highlights
- Innovative Approach: The SeekInClarity test integrates genomic, epigenetic, and proteomic signals from blood samples to calculate a molecular tumor burden (MTB) score, offering a non-invasive alternative to traditional imaging-based assessments.
- Clinical Validation: In a cohort of 116 newly diagnosed lymphoma patients, higher MTB scores strongly correlated with advanced tumor stage. Patients whose MTB status remained positive after two treatment cycles had significantly worse progression-free and overall survival.
- Superior Risk Stratification: The study found that molecular response, as measured by SeekInClarity, and interim PET/CT were the only independent predictors of treatment outcome—outperforming established clinical biomarkers such as B2M and LDH.
- Added Value Beyond Imaging: Among patients with interim PET/CT response, SeekInClarity identified a subgroup of molecular non-responders who were at substantially higher risk of disease progression, particularly in aggressive lymphoma subtypes.
Clinical Impact
Current standards for monitoring lymphoma rely on PET-CT or CT imaging, which can be costly and have limitations in sensitivity. The SeekInClarity assay provides a cost-effective, pan-indication blood test that can refine risk stratification and enable earlier intervention for patients unlikely to respond to standard therapies.
“Our findings underscore the clinical value of integrating multi-omics liquid biopsy approaches like SeekInClarity into routine lymphoma management,” said Dr. Mao Mao, corresponding author and Founder & CEO at SeekIn Inc. “This tool can identify high-risk patients earlier and more accurately than current methods, guiding more personalized treatment decisions.” The study was a collaborative effort involving leading hospitals in China. The publication can be found at https://doi.org/10.1186/s12885-025-14457-6.
About the Study
The study prospectively enrolled 116 lymphoma patients from two major cancer centers in China. Blood samples were collected before and after two cycles of treatment to assess changes in the MTB score. The results were validated against interim PET/CT imaging and standard clinical biomarkers. SeekInClarity’s molecular response framework demonstrated robust predictive power for both progression-free and overall survival, especially in aggressive B-cell and NK/T-cell lymphomas.
Looking Ahead
This research paves the way for broader adoption of blood-based multi-omics monitoring in lymphoma and potentially other cancers, offering clinicians a powerful new tool to optimize patient outcomes.
About SeekInClarity
SeekInClarity is a blood-based, pan-cancer, pan-indication test designed to monitor treatment response in cancer patients. Utilizing a cutting-edge, multivariable molecular tumor burden (MTB) algorithm, SeekInClarity provides a comprehensive assessment of therapeutic efficacy across a broad spectrum of cancers and treatment regimens—including chemotherapy, targeted therapy, immunotherapy, and combination therapies. The MTB model leverages shallow whole-genome sequencing (sWGS) of cell-free DNA to map the panoramic cancer genome. It integrates analysis of copy number aberrations (CNA), fragment size (FS), and seven protein biomarkers to deliver a robust, real-time prediction of tumor burden and treatment response in patients with advanced cancers. SeekInClarity received CE-IVD Mark in May 2022.
About SeekIn
SeekIn Inc. is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing next-generation sequencing and artificial intelligence. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn has also developed novel molecular tests for leukemia patients and its cancer early detection technology has also successfully been applied to canines. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in China. SeekIn envisions that, by leading a new norm for cancer early detection, the clinical outcomes of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s cutting-edge technologies and products, visit www.seekincancer.com.
SOURCE SeekIn Inc
